A prospective study of risk factors for cardiovascular events among the elderly

Marcos Aparecido Sarria Cabrera¹
Selma Maffei de Andrade²
Arthur Eumann Mesas²

¹Discipline of Geriatrics, Postgraduate Program in Public Health,
²Department of Public Health, Postgraduate Program in Public Health, Universidade Estadual de Londrina, Paraná, Brazil

Objective: To analyze the impact of cardiovascular (CV) risk factors on the occurrence of fatal and non-fatal CV events in elderly individuals.

Methods: The present research was a prospective cohort study of 800 elderly Brazilian outpatients (60 to 85 years old) with a 12-year follow-up period (baseline: 1997–1998). The outcome variable was CV mortality or non-fatal CV events (stroke, infarction, angina, heart failure). Hypertension, diabetes, global and abdominal obesity, dyslipidemias, and metabolic syndrome were analyzed as independent variables. The analyses were based on Cox proportional hazard models and adjusted for gender, age range, smoking, regular physical activity, and previous cardiovascular disease.

Results: A total of 233 fatal and non-fatal CV events were observed (29.1%). In the adjusted analysis, the following variables were associated with CV risk: hypertension hazard ratio (HR): 1.69; confidence interval (CI) 95%: 1.28–2.24, diabetes (HR: 2.67; CI 95%: 1.98–3.61), metabolic syndrome (HR: 1.61; CI 95%: 1.24–2.09), abdominal obesity (HR: 1.36; CI 95%: 1.03–1.79), hypertriglyceridemia (HR: 1.67; CI 95%: 1.22–2.30) and high triglyceride/HDL-c ratio (HR: 1.73; CI 95%: 1.31–2.84). Hypertension, diabetes, and dyslipidemia remained associated with CV risk regardless of abdominal obesity.

Conclusion: In this prospective study, hypertension, diabetes, metabolic syndrome, abdominal obesity, and hypertriglyceridemia were predictors of CV risk in elderly individuals. These results confirm the relevance of controlling these CV risk factors in this age group.

Keywords: aged, cardiovascular diseases, risk factors, epidemiology

Introduction

Cardiovascular diseases (CVD) represent the main cause of mortality, morbidity, and health resource utilization in elderly individuals.¹ Strategies for confronting these diseases involve the acknowledgment of factors associated with higher risk of arteriosclerotic disease and their subsequent control.

Some modifiable risk factors, such as sedentary habits, smoking, hypertension, diabetes, dyslipidemias, and obesity can be identified in the general population, all of which can be intervened upon by health care services.² Among the elderly, even though the role of some of these factors has not been clearly defined, the effectiveness of acting on risk factors to reduce CVD has already been recognized.³

Many researchers have studied the epidemiological aspects of CVD in depth; however, the elderly are frequently excluded from such studies, particularly those who present compromised functional capacity and comorbidities.⁴
The objective of this study was to carry out a prospective analysis of the determinants of cardiovascular (CV) events among the elderly, considering the interference of several previously known factors.

Methods
Design and setting
The present research was a prospective cohort study with a 12-year follow-up period. The sample consisted of elderly outpatients (60 to 85 years old) from two geriatric clinics with similar characteristics in the city of Londrina, in southern Brazil. All patients admitted to the clinics between June 1997 and June 1998 were analyzed. The exclusion criteria were: age over 85 years, the presence of active neoplasia (except in the skin and prostate), and the inability to remain standing for the anthropometric measurements.

Measurement
The following variables were analyzed.

Confounding variables
Gender, age range (60 to 74, 75 and over), regular physical activity (at least three times a week), smoking, and the presence of previous CVD (heart failure, atrial fibrillation, coronary artery disease, myocardial infarction, or stroke).

Independent variables
Hypertension: individuals were considered to have hypertension when using antihypertensive medications and/or presenting systolic blood pressure ≥ 140 mm/Hg and diastolic blood pressure ≥ 90 mm/Hg.

Diabetes: fasting glycemia ≥ 126 mg/dL or the use of anti-diabetic medications.

Pre-diabetes: fasting glycemia ≥ 100 mg/dL
Metabolic syndrome (MS): patients presenting at least three of the following disorders were considered to have MS: (1) hypertension; (2) hypertriglyceridemia (≥150 mg/dL); (3) high density lipoprotein-cholesterol (HDL-c) <50 mg/dL for women and <40 mg/dL for men; (4) fasting glucose ≥ 100 mg/dL; and (5) waist circumference > 88 cm for women and >102 cm for men.

Obesity and overweight: individuals whose body mass index (BMI) was ≥30 and ≥27 kg/m², respectively.

Abdominal obesity: The waist circumference (WC) and the waist–hip ratio (WHR) were obtained and abdominal obesity was determined using the 75th percentile (differentiated by gender) as a cutoff point.

Lipids: the serum lipid levels (total cholesterol, HDL-c, and triglycerides) were obtained with the enzymatic method after a 12-hour fast. In order to calculate low-density lipoprotein (LDL-c), the Friedwald formula was used for individuals with triglycerides < 400 mg/dL. Dyslipidemias were classified according to different cutoff points: total cholesterol > 200 mg/dL and >240 mg/dL; LDL-c > 100 mg/dL and >130 mg/dL; HDL-c < 40 mg/dL and <35 mg/dL; and triglycerides > 200 mg/dL. A triglycerides/HDL-c ratio > 4 was also analyzed as a variable related to lipid disorders.

Dependent variable: occurrence of a fatal or non-fatal CV event. Patient follow up occurred every 6 months. Events were identified by the researchers’ direct observation, reports by health services, or information gathered from relatives.

The CV events evaluated as outcomes were:
• CV mortality
  The following deaths were considered to be of CV origin:
  a. deaths whose underlying causes are cataloged in the tenth review of the International Classification of Diseases (ICD-10), chapter IX, codes 100 through 199, which correspond to CVDs;
  b. deaths whose underlying cause was diabetes (ICD-10, chapter IV, codes E10–E14), but the final cause of death being classified as a CVD (ICD-10 codes 100–199);
  c. sudden deaths, ie, those that occurred up to one hour after the beginning of symptoms with no evidence of other non-CV causes.
• Non-fatal events
  a. Stroke – The study considered events of ischemic or hemorrhagic origin that presented neurological symptoms for at least 24 hours and were the cause of hospital admission.
  b. Coronary artery disease – Patients who presented a clinical condition suggesting coronary artery disease, confirmed by at least one of the following complementary exams: exercise testing, myocardial scintigraphy, or cardiac catheterization. Patients submitted to coronary angioplasty were also considered to have coronary artery disease.
  c. Myocardial infarction – Diagnosis and treatment for myocardial infarction by a medical service that included a record of hospital admission.

When more than one event happened to the same individual during the follow-up period, the first episode was considered for analysis.

Statistical analysis
The results were obtained by analyzing the Cox proportional hazard model, in which death of non-CV origin and follow-
up loss were considered censoring. The fatal and non-fatal CV events observed were analyzed together as the dependent variable. Hypertension, diabetes, MS, and dyslipidemias were considered independent variables. The analysis models were adjusted for gender, age range > 75 years, the presence of previous CVD, smoking, and regular physical activity.

The components of MS were also analyzed using a multivariate model that included statistically significant variables, such as diabetes, hypertension, abdominal obesity (WHR), and hypertriglyceridemia, in the adjusted model. The first model (A) included hypertriglyceridemia and the triglycerides/HDL-c ratio was analyzed in the second model (B).

The significance level used was 5% ($\alpha = 0.05$); the data were analyzed in EpiInfo 3.5.

**Ethical aspects**

The study was approved by the Research Ethics Committee of the Universidade Estadual de Londrina and Universidade de São Paulo and followed the Helsinki Declaration guidelines. At the initial follow up, the patients and/or their guardians were informed about the study design and signed an informed consent form.

**Results**

A total of 901 patients were admitted to both outpatient geriatric clinics from June 1997 to June 1998. There were 40 exclusions due to cancer diagnosis at the baseline (26 females, 14 males) and 61 because patients were older than 85 years (42 females, 19 males).

The final sample included 800 individuals aged 60 to 85 years (mean 71.2; median 70.5); 534 of whom were females (66.8%). Thirty-one participants (3.9%) did not complete the follow up and they were analyzed as censoring. The mean follow-up time was 11.8 years.

The total mortality during follow up was 339 (42.9%) and 132 deaths were of CV origin (38.9%). The following non-fatal CV events were observed: stroke (72), myocardial infarction (23), coronary artery disease (55), and recent heart failure (24). Therefore, the fatal and non-fatal events were registered as the main outcome for analysis in 233 elderly individuals (29.1%). Table 1 presents the characteristics of the participants at the beginning of follow up.

The risk of CV events was statistically significant for the following variables: diabetes (HR: 2.67; CI 95%: 1.98–3.61; $P < 0.001$), pre-diabetes or diabetes (HR: 1.60; CI 95%: 1.23–2.08; $P < 0.001$), hypertension (HR: 1.69; CI 95%: 1.28–2.24; $P < 0.001$), MS (HR: 1.61; CI 95%: 1.24–2.09; $P < 0.001$), increased WHR (HR: 1.36; CI 95%: 1.03–1.79; $P < 0.05$), hypertriglyceridemia (HR: 1.67; CI 95%: 1.22–2.30; $P < 0.01$), and high triglyceride/HDL-c ratio (HR: 1.73; CI 95%: 1.31–2.84; $P < 0.001$). No significant associations were observed for global obesity, overweight, abdominal obesity measured by WC, hypercholesterolemia, increased LDL-c, or decreased HDL-c (Table 2).

In the multivariate analysis adjusted for gender, age range, smoking, previous CVD, and regular physical activity, it was observed that hypertension ($P < 0.05$) and diabetes ($P < 0.001$) remained significantly associated with the occurrence of CV events. Additionally, hypertriglyceridemia – model A (HR: 1.48; CI 95%: 1.07–2.04; $P < 0.05$) and a triglycerides/HDL-c ratio $> 4$ – model B (HR: 1.56; CI 95%: 1.17–2.08; $P < 0.05$) also showed an independent association with CV risk. Abdominal obesity was not associated, regardless of the other factors, and MS was not included in the multivariate models since it presented direct collinearity with the other included factors (Table 3).

**Discussion**

The results reveal a particular profile of CV risk in this group of elderly individuals < 85 years old. The data reinforce the role of diabetes, hypertension, MS, and abdominal obesity as determinants of CV risk among the elderly. In addition, among the dyslipidemias, only hypertriglyceridemia and a

### Table 1 Baseline characteristics of the participants

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total (n = 800)</th>
<th>CV events (n = 233)</th>
<th>No CV events (n = 567)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y), mean ± SE</td>
<td>71.2 (6.9)</td>
<td>72.9 (6.5)</td>
<td>70.5 (7.0)</td>
</tr>
<tr>
<td>Women %</td>
<td>66.8</td>
<td>63.1</td>
<td>68.3</td>
</tr>
<tr>
<td>Hypertension %</td>
<td>53.9</td>
<td>67.0</td>
<td>48.5</td>
</tr>
<tr>
<td>Diabetes %</td>
<td>15.1</td>
<td>25.1</td>
<td>11.0</td>
</tr>
<tr>
<td>CVD history %</td>
<td>17.1</td>
<td>30.5</td>
<td>12.0</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL) mean ± SE</td>
<td>205.8 (43.3)</td>
<td>206.8 (47.0)</td>
<td>205.4 (41.7)</td>
</tr>
<tr>
<td>LDL-c (mg/dL) mean ± SE</td>
<td>126.6 (37.6)</td>
<td>126.8 (38.8)</td>
<td>126.5 (37.1)</td>
</tr>
<tr>
<td>HDL-c (mg/dL) mean ± SE</td>
<td>49.9 (14.1)</td>
<td>48.1 (14.3)</td>
<td>50.7 (14.0)</td>
</tr>
<tr>
<td>Triglycerides (mg/dL) mean ± SE</td>
<td>146.5 (84.0)</td>
<td>159.2 (100.5)</td>
<td>141.2 (75.5)</td>
</tr>
<tr>
<td>BMI (kg/m²) mean ± SE</td>
<td>25.9 (4.8)</td>
<td>26.2 (4.8)</td>
<td>25.8 (4.8)</td>
</tr>
<tr>
<td>Waist circumference (cm) mean ± SE</td>
<td>92.2 (10.8)</td>
<td>94.1 (10.9)</td>
<td>91.4 (10.7)</td>
</tr>
<tr>
<td>Waist-to-hip ratio mean ± SE</td>
<td>0.941 (0.06)</td>
<td>0.955 (0.06)</td>
<td>0.936 (0.06)</td>
</tr>
<tr>
<td>Metabolic syndrome %</td>
<td>38.9</td>
<td>48.9</td>
<td>34.7</td>
</tr>
<tr>
<td>Regular physical activity %</td>
<td>21.8</td>
<td>23.3</td>
<td>18.0</td>
</tr>
<tr>
<td>Smoking %</td>
<td>7.6</td>
<td>8.2</td>
<td>6.4</td>
</tr>
</tbody>
</table>

**Notes:** $\beta < 0.05$; $\gamma < 0.01$; $\delta < 0.001$.

**Abbreviations:** CV, cardiovascular; SD, standard error; CVD, cardiovascular disease; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; BMI, body mass index.
high triglycerides/HDL-c ratio showed an association with increased CV risk.

Factors associated with higher CV risk in the bivariate analysis were still associated even after controlling for other important determinants of CV health, such as age, smoking, and sedentary habits. Moreover, adjustment due to the presence of previous CVD (observed in 17% of the participants) minimized the possible influence of pathological situations diagnosed before the follow-up period.

Diabetes has been highlighted as one of the most significant factors in CV risk, and the results of the present study confirm this risk, even when individuals with glycemia ≥ 100 mg/dL were included in the risk variables. Other authors have also identified this risk pattern in different groups of elderly individuals; in a study of CVD-free elderly individuals with a 15-year follow up, diabetes and hypertension were associated with a higher risk of CV events. 10

The risk of CV events in this study was associated with the presence of hypertension, which is consistent with another study on the elderly. 11 In addition, the present prospective analysis showed that diabetes and hypertension increased CV risk regardless of the other components of MS, such as abdominal obesity and hypertriglyceridemia.

As in the general population, abdominal obesity appeared as a CV risk factor. However, in this group of elderly individuals, a statistically significant association was observed when abdominal obesity was determined by WHR and not abdominal circumference. WHR has already been indicated as a better predictor of obesity-associated risk in elderly individuals. 12

Overweight was not identified as a CV risk factor, even though two different levels of BMI were examined (≥ 27 and ≥ 30 kg/m²). Many authors have already demonstrated that global obesity does not represent an independent CV risk factor in elderly individuals. 13,14 However, a study of elderly Chinese individuals found a positive association between BMI and CV risk, 15 showing that BMI can still be a good CVD marker in certain ethnicities.

Furthermore, situations related to hyperglycemia, higher levels of blood pressure, and abdominal obesity were associated with higher CV risk. Thus, MS, which represents their combined expression, was also significantly associated with the analyzed outcomes. In a preliminary analysis, after five years of follow up that included only women, an association between MS and CV events was observed. 16

MacNeill et al also confirmed that MS is an indicator of CV risk in elderly individuals, since hypertension was the component that most affected the occurrence of CVD in their follow up. 17 Although there are different classifications of MS, all of them result in an evident increase of CV risk in elderly individuals. 18,19

### Table 2 Association between cardiovascular events and classic risk factors in older adults (n = 800)

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>%</th>
<th>HR crude (CI 95%)</th>
<th>HR adjusted* (CI 95%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>53.9</td>
<td>1.83 (1.39; 2.41)</td>
<td>1.69 (1.28; 2.24)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>15.1</td>
<td>2.60 (1.93; 3.50)</td>
<td>2.67 (1.98; 3.61)</td>
</tr>
<tr>
<td>Pre-diabetes (GBL ≥ 100 mg/dL or diabetes)</td>
<td>33.0</td>
<td>1.74 (1.34; 2.26)</td>
<td>1.60 (1.23; 2.08)</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>38.9</td>
<td>1.59 (1.23; 2.06)</td>
<td>1.61 (1.24; 2.09)</td>
</tr>
<tr>
<td>Obesity (BMI ≥ 30 kg/m²)</td>
<td>18.3</td>
<td>0.99 (0.71; 1.38)</td>
<td>1.05 (0.75; 1.47)</td>
</tr>
<tr>
<td>Overweight (BMI ≥ 27 kg/m²)</td>
<td>37.3</td>
<td>0.99 (0.76; 1.29)</td>
<td>1.06 (0.81; 1.39)</td>
</tr>
<tr>
<td>WC ≥ 75th percentile</td>
<td>25.9</td>
<td>1.21 (0.91; 1.61)</td>
<td>1.21 (0.91; 1.62)</td>
</tr>
<tr>
<td>Waist-hip ratio ≥ 75th percentile</td>
<td>26.6</td>
<td>1.45 (1.10; 1.91)</td>
<td>1.36 (1.03; 1.79)*</td>
</tr>
<tr>
<td>Total cholesterol &gt; 200 mg/dL</td>
<td>48.9</td>
<td>0.93 (0.72; 1.21)</td>
<td>1.10 (0.84; 1.43)</td>
</tr>
<tr>
<td>Total cholesterol &gt; 240 mg/dL</td>
<td>21.5</td>
<td>1.07 (0.79; 1.44)</td>
<td>1.32 (0.97; 1.79)</td>
</tr>
<tr>
<td>LDL-c &gt; 100 mg/dL</td>
<td>69.5</td>
<td>0.83 (0.63; 1.09)</td>
<td>0.93 (0.70; 1.23)</td>
</tr>
<tr>
<td>LDL-c &gt; 130 mg/dL</td>
<td>41.3</td>
<td>1.04 (0.80; 1.35)</td>
<td>1.20 (0.93; 1.57)</td>
</tr>
<tr>
<td>HDL-c ≥ 45 mg/dL</td>
<td>34.8</td>
<td>1.36 (1.05; 1.77)</td>
<td>1.23 (0.94; 1.61)</td>
</tr>
<tr>
<td>HDL-c ≥ 40 mg/dL</td>
<td>22.8</td>
<td>1.38 (1.04; 1.79)</td>
<td>1.27 (0.94; 1.70)</td>
</tr>
<tr>
<td>HDL-c ≥ 35 mg/dL</td>
<td>12.6</td>
<td>1.53 (1.08; 2.16)</td>
<td>1.26 (0.89; 1.79)</td>
</tr>
<tr>
<td>Triglycerides &gt; 200 mg/dL</td>
<td>16.5</td>
<td>1.39 (1.01; 1.90)</td>
<td>1.67 (1.22; 2.30)*</td>
</tr>
<tr>
<td>Triglycerides/HDL-c &gt; 4</td>
<td>23.5</td>
<td>1.62 (1.28; 2.13)</td>
<td>1.73 (1.31; 2.84)*</td>
</tr>
</tbody>
</table>

Notes: *P < 0.05; †P < 0.01; ‡P < 0.001. Cox regression models adjusted for sex, age, cardiovascular disease history, regular physical activity, and smoking.

Abbreviations: HR, hazard ratio; GBL, glucose blood level; BMI, body mass index; WC, waist circumference; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol.

### Table 3 Multivariate analysis of the risk of fatal and non-fatal cardiovascular events regarding hypertension, diabetes, abdominal obesity and hypertriglyceridemia

<table>
<thead>
<tr>
<th>Independent variables</th>
<th>Dependent variable – cardiovascular events</th>
<th>HR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
<td>1.53</td>
<td>1.15–2.03</td>
</tr>
<tr>
<td>Diabetes</td>
<td></td>
<td>2.12</td>
<td>1.56–2.88</td>
</tr>
<tr>
<td>WHR – percentile 75</td>
<td></td>
<td>1.17</td>
<td>0.89–1.55</td>
</tr>
<tr>
<td>Triglycerides &gt; 200 mg/dL</td>
<td></td>
<td>1.48</td>
<td>1.07–2.04</td>
</tr>
<tr>
<td>Model B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
<td>1.54</td>
<td>1.16–2.05</td>
</tr>
<tr>
<td>Diabetes</td>
<td></td>
<td>2.08</td>
<td>1.53–2.83</td>
</tr>
<tr>
<td>WHR – percentile 75</td>
<td></td>
<td>1.11</td>
<td>0.84–1.48</td>
</tr>
<tr>
<td>Triglycerides/HDL-c &gt; 4</td>
<td></td>
<td>1.56</td>
<td>1.17–2.08</td>
</tr>
</tbody>
</table>

Note: *Adjusted for gender, age range ≥ 75 years old, smoking, previous cardiovascular disease, and regular physical activity.

Abbreviations: WHR, waist-hip ratio; HDL-c, high-density lipoprotein cholesterol; ns, non-significant.
Hypercholesterolemia and increased LDL-c have been cited as important CV risk factors, and their pharmacological control represents an important tool for preventing primary or secondary CV disorders. However, the results of the present study did not show significant associations between high levels of total cholesterol and LDL-c and the incidence of CV events.

This weak association could not be the consequence of a possible smaller role of lipoproteins in the arteriosclerosis process, since this role is widely documented in the literature. Thus, it may be due to the influence of low cholesterol on mortality levels in elderly individuals, which was recently observed in the same sample. In this age range, low cholesterol appears to be a greater predictor of morbi-mortality than higher levels since it is frequently associated with malnutrition, fragility, and sub-clinical diseases.

The association between hypercholesterolemia and CVD has been studied several times in the elderly, but the mechanisms to explain this association is still not clear. In a study on elderly individuals with a 13-year follow up, higher CV risk was observed for high total cholesterol and low HDL-c.

On the other hand, in agreement with the present findings, other authors did not identify high total cholesterol and LDL-c as CV risk factors in elderly individuals. For example, Veeranna et al did not observe an association between dyslipidemia and severity of coronary injury in elderly individuals. In another study with elderly diabetics, there was an association with CV risk for LDL-c and HDL-c levels in elderly individuals up to 75 years old, but the association was not significant in individuals over the age of 75 years, as was also observed in the present study.

Our analysis possibly did not have the statistical power to identify an association between low HDL-c levels and CV risk in the adjusted analysis. A low HDL-c level is widely acknowledged as an important CV risk factor among the elderly, and a number of authors have already demonstrated this association.

Among the dyslipidemias, hypertriglyceridemia was significantly associated with the occurrence of CV events, regardless of the presence of diabetes, hypertension, or abdominal obesity. Few authors have studied the independent association between triglycerides and CVD in the elderly. Mazza et al identified a high level of triglycerides as an indicator of higher CV risk among elderly women, although their results for men were not significant. Even though dealing with hypertriglyceridemia is important, it has not been fully explored by the primary and secondary prevention guidelines, particularly among geriatric populations.

In addition to high triglyceride levels, the ratio between serum triglycerides and HDL-c levels was also associated with higher CV risk. The triglyceride/HDL-c ratio indirectly reflects the levels of phenotype B low-density lipoprotein particles, which are smaller and denser. This ratio plays a fundamental role in arteriosclerosis and is associated with an important increase in CV risk.

Recognizing the triglyceride/HDL-c ratio as an independent CV risk factor allows the proper determination of CV risk by means of an inexpensive, easy, and efficient method, which has been studied by several authors.

Although the results of the present study may contribute to a better understanding of the epidemiology of CVDs in the elderly, some limitations must be mentioned. The sample represents a group of elderly outpatients and was not population-based. Nevertheless, these subjects present socio-demographic characteristics and comorbidities similar to those of the general elderly population. Another methodological question that could interfere in the results is that sub-clinical CV events were not identified. Their acknowledgment, even though very difficult from a methodological point of view, could have contributed to the data analysis. The outcome events were not reviewed by an independent expert committee. Lastly, this study did not consider the therapeutic regimens used to control hypertension, diabetes, and dyslipidemias, or the level of adherence to pharmacological treatment, which could have interfered with the occurrence of complications.

As the roles of some determinants of CVD are defined, the importance of preventive measures stands out. Thus, unlike what is commonly observed, CVD prevention in older individuals should be intensified, and could generate many benefits for people in this age range as well.

These results help consolidate the importance of the main CV risk factors in elderly populations and underscore the relevance of measures to prevent CVD and promote fewer comorbidities during the aging process.

Disclosure
The authors report no conflicts of interest in this work.

References


